Shots:

• The P-III CheckMate -648 trial involves assessing Opdivo (nivolumab) + CT or Opdivo (3 mg/kg- q2w) + Yervoy (1 mg/kg- q6w up to 24mos.) in patients with unresectable advanced or metastatic ESCC
• Results: Both the combinations demonstrated OS benefits in PD-L1 positive and all-randomized populations
• Additionally- Opdivo + CT met its 1EP of PFS while Opdivo + Yervoy failed to meet its 1EPs of PFS. The safety profiles of Opdivo and the combination of Opdivo and Yervoy were consistent with previously reported studies

  Ref: BMS | Image: BMS